Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H10FN3O5 |
| Molecular Weight | 247.1805 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1[C@H](O)[C@H](O[C@@H]1CF)N2C=CN=C2[N+]([O-])=O
InChI
InChIKey=LPZSRGRDVVGMMX-JWXFUTCRSA-N
InChI=1S/C8H10FN3O5/c9-3-4-5(13)6(14)7(17-4)11-2-1-10-8(11)12(15)16/h1-2,4-7,13-14H,3H2/t4-,5-,6+,7+/m1/s1
1‐α‐D‐(5‐Fluoro‐5‐deoxyarabinofuranosyl)‐2‐nitroimidazole (fluoroazomycin arabinoside, FAZA) is a putative PET imaging agent when labelled with 18F. Fluoroazomycin arabinoside is essential in the generation of fluorine F 18-fluoroazomycin arabinoside (18F-FAZA), which is a radiofluorinated 2-nitroimidazole derivative with hypoxia (low oxygen)-specific tracer activity. 18F-FAZA is reduced under hypoxic conditions, forming highly reactive intermediates. In its reduced form, 18F-FAZA covalently binds to macromolecules, thereby accumulating in hypoxic cells (e.g. malignant tumors) and allowing radioisotopic imaging of these particular cells with positron emission tomography (PET).
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
220793-03-3
Created by
admin on Mon Mar 31 22:03:47 GMT 2025 , Edited by admin on Mon Mar 31 22:03:47 GMT 2025
|
PRIMARY | |||
|
1QR3UU6P48
Created by
admin on Mon Mar 31 22:03:47 GMT 2025 , Edited by admin on Mon Mar 31 22:03:47 GMT 2025
|
PRIMARY | |||
|
10083297
Created by
admin on Mon Mar 31 22:03:47 GMT 2025 , Edited by admin on Mon Mar 31 22:03:47 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
